Vepdegestrant (ARV-471) is an oral estrogen receptor PROTAC protein degrader for breast cancer. Vepdegestrant (ARV-471) is a heterobifunctional molecule that promotes the interaction between estrogen receptor alpha and intracellular E3 ligase complexes. Vepdegestrant (ARV-471) causes ubiquitination and subsequent degradation of the estrogen receptor via the proteasome. Vepdegestrant (ARV-471) potently degrades ER-positive The ER in breast cancer cell lines is potently degraded by ARV-471 with a DC50 value of approximately 2 nM.
Molecular Weight | 723.9 |
Formula | C45H49N5O4 |
CAS Number | 2229711-68-4 |
Solubility (25°C) | DMSO 90 mg/mL |
Storage | -20°C, protect from light, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] Diego Garcia Jimenez, et al. ADMET DMPK. Are we ready to design oral PROTACs®?
Related PROTAC Products |
---|
DGY-09-192
DGY-09-192 is a bivalent degrader that couples the pan-FGFR inhibitor BGJ398 to the CRL2VHL E3 ligase-recruiting ligand, which induces degradation of FGFR1/2 and largely avoids degradation of FGFR3/4.DGY-09-192 exhibits a nanomolar DC50 against both wild-type FGFR2 and several FGFR2 fusions. In addition, DGY-09-192 has antiproliferative activity in gastric and cholangiocarcinoma cells. |
BTX-6654
BTX-6654 is a targeted and specific cerebellar-based bifunctional SOS1 PROTAC degrader.BTX-6654 reduces the downstream signaling markers pERK and pS6 and displays antiproliferative activity in a wide range of KRAS-mutant cells. |
ND1-YL2
ND1-YL2 is a PROTAC that selectively degrades SRC-1 via the N-degron pathway. |
PRT3789
PRT3789 is a PROTAC degrader targeting SMARCA2 with more than 1,000-fold selectivity for SMARCA2 compared to SMARCA4 at the cellular level for studies related to non-small cell lung cancer (NSCLC). |
KT-294
KT-294 is a potential first-in-class, PROTAC protein degrader targeting TYK2 for research related to immune system diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.